title: Response to oral supplementation in copper deficiency myeloneuropathy.
abstract: Neurological manifestations due to copper deficiency include ataxic myeloneuropathy that resembles subacute combined degeneration due to B12 deficiency. We report our experience in the treatment of 10 patients with copper deficiency myeloneuropathy and conclude that copper supplementation leads to stabilization rather than improvement in the neurological deficits.
authors.affiliation: Noran Neurological Clinic and University of Minnesota, Minnesota, MN 55432-2769, USA. pkelkar@noranclinic.com
authors.forename: Praful
authors.initials: P
authors.lastname: Kelkar
authors.forename: Shereen
authors.initials: S
authors.lastname: Chang
authors.forename: Suraj A
authors.initials: SA
authors.lastname: Muley
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D003300:Copper / Q000008:administration & dosage* / Q000097:blood / Q000172:deficiency*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013118:Spinal Cord Diseases / Q000188:drug therapy* / Q000209:etiology*; D016896:Treatment Outcome
chemical_list: D003300:Copper